Kalaris Therapeutics Inc (KLRS) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Kalaris Therapeutics Inc (KLRS) Earnings Overview
As of June 13, 2026, Kalaris Therapeutics Inc (KLRS) reported trailing twelve-month net income of -$44M, reflecting +75.7% year-over-year growth. The company earned $-1.86 per diluted share over the past four quarters.
Looking at the long-term picture, KLRS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2018.
Kalaris Therapeutics Inc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including REPL (-$315M net income), ADMA ($165M net income, 28.8% margin), TGTX ($462M net income, 72.6% margin), KLRS has comparable earnings metrics. Compare KLRS vs REPL →
KLRS Earnings vs Peers
Earnings metrics vs comparable public companies
KLRS Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$43M | +26.1% | -$46M | $-2.85 | - | - |
| 2024 | -$59M | -299.8% | -$55M | $-11.73 | - | - |
| 2023 | -$15M | +5.1% | -$13M | $-42.09 | - | - |
| 2022 | -$15M | +91.0% | -$14M | $-50.62 | - | - |
| 2021 | -$172M | -146.4% | -$170M | $-63.00 | - | - |
| 2020 | -$70M | -192.7% | -$71M | $-59.67 | - | - |
| 2019 | -$24M | -881.0% | -$27M | $-8.42 | -14447.9% | -16182.4% |
| 2018 | -$2M | - | -$4M | $-2.88 | -214.1% | -316.8% |
Download Data
Export KLRS earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in KLRS back in 2018?
Total return with dividends reinvested · 8+ years of data
Calculate ReturnsHow much would $100/month in KLRS be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs KLRS Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationKLRS vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowKLRS — Frequently Asked Questions
Quick answers to the most common questions about buying KLRS stock.
What is KLRS earnings per share (EPS)?
KLRS trailing twelve-month (TTM) diluted EPS is $-1.86, reflecting +75.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Kalaris Therapeutics Inc's net income?
Kalaris Therapeutics Inc (KLRS) trailing twelve-month net income is $-44M as of 2025. Earnings grew +75.7% year-over-year.
Is KLRS profitable?
KLRS is not currently profitable on a TTM basis, reporting a net loss of $-44M. Net margin is N/A. Investors should monitor for a return to profitability.
What is KLRS's earnings growth rate?
KLRS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are KLRS's profit margins?
Kalaris Therapeutics Inc net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -45.2%.
Is KLRS growing earnings?
Yes, KLRS earnings are accelerating — EPS growth of +75.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-44M. Earnings momentum is strengthening.
What was KLRS's best earnings year?
Kalaris Therapeutics Inc's highest annual net income on record is $-2M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were KLRS's earnings last quarter?
KLRS's most recent reported quarter was Q1 2026. Net income was $-11M with diluted EPS of $-0.46. For a full breakdown of all quarters, see the quarterly earnings table on this page.